Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination

Vaccine

Volumn 28, Issue 42, 2010, Pages 6885-6890

  Morelon, Emmanuel ^a,b,f,g   Noble, Claire Pouteil ^a,c,g   Daoud, Sameh ^a,b   Cahen, Remi ^a,c   Goujon Henry, Catherine ^c   Weber, Françoise ^d   Laurent, Philippe E ^e   Kaiserlian, Dominique ^f,g   Nicolas, Jean François ^c,f,g  

^a UNIVERSITÉ DE LYON   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d SANOFI PASTEUR   (France)

^e Becton Dickinson Pharmaceutical Systems   (France)

^f University Lyon i   (France)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

Influenza vaccine; Intradermal injection; Renal transplant patients

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMAGGLUTINATION INHIBITING ANTIBODY; IDFLU; INFLUENZA VACCINE; INTANZA; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SEX RATIO; SHIVERING; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; VACCINATION; VACCINES, INACTIVATED;

EID: 77956884239     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.015     Document Type: Article

References (23)

1. Thompson W.W., Shay D.K., Weintraub E., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(2):179-186.
2. Thompson W.W., Shay D.K., Weintraub E., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292(11):1333-1340.
3. Fiore A.E., Shay D.K., Broder K., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009, 58(RR-8):1-52.
4. Fleming D.M., Elliot A.J. Lessons from 40 years' surveillance of influenza in England and Wales. Epidemiol Infect 2008, 136(7):866-875.
5. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9(8):493-504.
6. Duchini A., Goss J.A., Karpen S., Pockros P.J. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003, 16(3):357-364.
7. Sester M., Gartner B.C., Girndt M., Sester U. Vaccination of the solid organ transplant recipient. Transplant Rev (Orlando) 2008, 22(4):274-284.
8. Hannoun C., Megas F., Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004, 103(1-2):133-138.
9. Stiver H.G., Graves P., Meiklejohn G., Schroter G., Eickhoff T.C. Impaired serum antibody response to inactivated influenza A and B vaccine in renal transplant recipients. Infect Immun 1977, 16(3):738-741.
10. Nicolas J.F., Guy B. Intradermal epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008, 7(8):1201-1214.
11. Holland D., Booy R., De Looze F., et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008, 198(5):650-658.
12. World Health Organization WHO manual on animal influenza diagnosis and surveillance, WHO/CDS/CDR/NCS/2002.5 2002, The World Health Organization, Geneva.
13. Laurent P.E., Bonnet S., Alchas P., et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007, 25(52):8833-8842.
14. Committee for Proprietary Medicinal Products (CPMP) Note for guidance for harmonization of requirements for influenza vaccines. CPMP/BWP/214/96 1997, EMEA, (GENERIC).
15. Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998, 17(8):857-872.
16. Birdwell K.A., Ikizler M.R., Sannella E.C., et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis 2009, 54(1):112-121.
17. Arnou R., Icardi G., De Decker M., et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009, 27(52):7304-7312.
18. Leroux-Roels I., Vets E., Freese R., et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine 2008, 26(51):6614-6619.
19. Danzinger-Isakov L., Kumar D. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009, 9(Suppl. 4):S258-S262.
20. Manuel O., Humar A., Chen M.H., et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant 2007, 7(11):2567-2572.
21. Gelinck L.B., van den Bemt B.J., Marijt W.A., et al. Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 2009, 27(18):2469-2474.
22. Belshe R.B., Newman F.K., Cannon J., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004, 351(22):2286-2294.
23. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351(22):2295-2301.